Page 19 - Column Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company...

Ribon Therapeutics, a Cambridge, Mass.-based clinical stage biotechnology company developing therapeutics targeting stress support pathways in cancer and inflammation, closed a $65m financing. The round was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures, along with existing investors AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, Johnson & Johnson Innovation – JJDC, Inc., Novartis Venture Fund, Osage University Partners, Takeda Ve...

July 1, 2021 July 1, 2021 | Insilico Medicine closes a Series C for AI-powered drug discovery, while other investments fuel remote access labs, natural products, high throughput screening, and more. $550M: VC Fund for Therapeutics for Unmet Needs venBio has announced the closing of venBio Global Strategic Fund IV, LP (“venBio Fund IV”), its fourth life sciences venture capital fund, exceeding its target and closing on approximately $550 million in capital commitments in an oversubscribed fundraise. The capital was raised from existing and new investors, including a broad rang...

Circle Pharma Raises $66M in Series C Financing Circle Pharma, Inc., a South San Francisco, Calif.-based macrocycle drug discovery and development company focused on intractable cancer targets, raised $66m in Series C financing. The round was co-led by The Column Group and Nextech Invest with participation from Pandect Bioventures, together with new investors including Euclidean Capital, Pavillion Capital, Hartford HealthCare Endowment and Eli Lilly and Company. The company intends to use the funds to advance its wholly owned cyclin-targeted programs towards the clinic, with potential applica...

SAN FRANCISCO, June 01, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein...